Cargando…
The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients. In this pilot study, we assessed with the ELISA method...
Autores principales: | Wencel-Warot, Agnieszka, Michalak, Slawomir, Warot, Marcin, Kalinowska-Lyszczarz, Alicja, Kazmierski, Radoslaw |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106061/ https://www.ncbi.nlm.nih.gov/pubmed/27828855 http://dx.doi.org/10.1097/MD.0000000000005337 |
Ejemplares similares
-
Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016) -
The Immunology of Neuromyelitis Optica—Current Knowledge, Clinical Implications, Controversies and Future Perspectives
por: Jasiak-Zatonska, Michalina, et al.
Publicado: (2016) -
The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications
por: Kalinowska-Lyszczarz, Alicja, et al.
Publicado: (2012) -
The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review
por: Kania, Karolina, et al.
Publicado: (2023) -
The associations between serum vascular endothelial growth factor, tumor necrosis factor and interleukin 4 with the markers of blood–brain barrier breakdown in patients with paraneoplastic neurological syndromes
por: Michalak, Slawomir, et al.
Publicado: (2018)